NCT06577766View on ClinicalTrials.gov

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

September 23, 2025

Study Completion Date

November 18, 2025

Conditions
ObesityOverweight
Interventions
DRUG

NNC0638-0355

NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection.

DRUG

Placebo (NNC0638-0355)

Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection.

Trial Locations (1)

78209

ICON, San Antonio

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT06577766 - A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity | Biotech Hunter | Biotech Hunter